Pediatric precision oncology-Time for clinical prime time

Stefan M Pfister; Olaf Witt; David T W Jones

doi:10.1016/j.medj.2022.07.004

Pediatric precision oncology-Time for clinical prime time

Med. 2022 Aug 12;3(8):521-522. doi: 10.1016/j.medj.2022.07.004.

Authors

Stefan M Pfister¹, Olaf Witt², David T W Jones³

Affiliations

¹ Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany. Electronic address: s.pfister@kitz-heidelberg.de.
² Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.

PMID: 35963231
DOI: 10.1016/j.medj.2022.07.004

Abstract

Recent prospective molecular tumor-profiling studies in pediatric cancer patients across a variety of different healthcare systems have highlighted both the feasibility and clinical utility of this approach. The current study by Church and colleagues in Nature Medicine¹ has further substantiated this and laid the groundwork for a systematic collaborative approach to pediatric precision oncology in the US.

Publication types

Comment

MeSH terms

Child
Humans
Medical Oncology
Neoplasms* / diagnosis
Precision Medicine